Chimerix Inc is a biopharmaceutical company that is committed to improving the lives of patients suffering from life-threatening diseases. Their corporate philosophy revolves around innovation, collaboration, and patient-centered care. Chimerix Inc values scientific excellence, integrity, and transparency in all aspects of their operations. They strive to develop novel antiviral therapies to address unmet medical needs. With a dedicated team of experts, Chimerix Inc focuses on delivering innovative solutions that can make a significant impact in the medical field. This commitment to patients, scientific advancement, and ethical practices defines Chimerix Inc and sets them apart in the biopharmaceutical industry.

Chimerix Inc is primarily present in the United States.

Chimerix Inc has achieved significant milestones throughout its history. One notable achievement was the successful completion of Phase 3 clinical trials for its antiviral drug, brincidofovir. This marked a crucial milestone in the company's efforts to develop an effective treatment for viral infections, including cytomegalovirus. Additionally, Chimerix Inc has secured multiple partnerships and collaborations with renowned healthcare organizations and research institutions. These partnerships have paved the way for further advancements in Chimerix's drug development pipeline and enhanced its potential to address unmet medical needs. Chimerix Inc continues to strive for further milestones and innovations in the field of antiviral therapeutics.

Chimerix Inc is a pharmaceutical company based in Durham, North Carolina. Founded in 2002, the company primarily focuses on the development and commercialization of innovative antiviral therapeutics. Chimerix has a rich history in the field of antiviral research and has made significant contributions to the medical community. The company's mission is to discover, develop, and deliver novel medicines to improve the lives of patients suffering from life-threatening diseases. With a dedicated team of scientists and researchers, Chimerix continues to advance its pipeline of antiviral drugs, providing hope for patients worldwide.

The main competitors of Chimerix Inc in the market include pharmaceutical companies such as Gilead Sciences, Merck & Co., and GlaxoSmithKline.

Chimerix Inc primarily operates in the biotechnology and pharmaceutical industries.

Chimerix Inc. operates with a business model focused on the development and commercialization of innovative antiviral therapeutics. The company aims to address unmet medical needs and improve patients' lives through the discovery, research, and development of novel antiviral medications. Chimerix Inc. primarily focuses on developing oral nucleotide analogs that target viral replication and replication pathways, aiming to provide effective treatments for various viral infections. With its commitment to advancing medical science, Chimerix Inc. leverages its expertise to create valuable pharmaceutical solutions, contributing to the advancement of antiviral therapeutics.

Το Chimerix P/E είναι -0,90.

Το KUV της εταιρείας Chimerix είναι 9,27.

Το AlleAktien Qualitätsscore για το Chimerix είναι 5/10.

Ο κύκλος εργασιών του αναμενόμενη Chimerix είναι 7,85 Εκ. USD.

Το αναμενόμενη Chimerix κέρδος είναι -80,59 Εκ. USD.

Chimerix Inc is a US biotech company specializing in the development of antiviral and immunoncology therapeutics. It was founded in 2000 and is headquartered in Durham, North Carolina. The company's business model focuses on the discovery, development, and commercialization of innovative therapies for infectious diseases and cancer. Chimerix operates in two main areas: infectious diseases and cancer. In infectious diseases, its leading product is Brincidofovir (BCV) for the treatment of life-threatening virus infections such as cytomegalovirus (CMV) and adenovirus infections. In cancer therapy, Chimerix has multiple products in its pipeline that aim to activate the immune system to fight tumors. The company collaborates with leading academic and clinical research institutions and utilizes various business models to market its products, including partnerships with government-funded research programs and multinational pharmaceutical companies. Overall, Chimerix has a promising pipeline of products in clinical studies and is well-positioned to improve global patient care.

Η Chimerix καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Chimerix αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Chimerix είναι US16934W1062.

Το WKN της Chimerix είναι A1T65B.

Ο τίκερ της Chimerix είναι CMRX.

Κατά τους τελευταίους 12 μήνες η Chimerix κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Chimerix προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Chimerix ανέρχεται σήμερα στο .

Chimerix πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Chimerix πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Chimerix ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Chimerix από την 5/8/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 5/8/2024.

Η τελευταία μερίσματος έγινε στις 5/8/2024.

Το έτος 2023, η Chimerix διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Chimerix καταβάλλονται σε USD.